A favorite in Alexion’s C-suite is leaving, and some mighty surprised analysts aren’t the least bit happy about it
Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
